Dr. Reddy’s Laboratories Ltd., founded in 1984 and headquartered in Hyderabad, India, is a leading multinational pharmaceutical company focused on providing affordable and innovative medicines. Its business model revolves around three core segments: Global Generics (~83% of revenue), Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company operates in over 66 countries, with key markets in the USA (47% of FY2024 revenue), India, Russia, and Europe.

Dr. Reddy’s excels in generics, biosimilars, and active pharmaceutical ingredients (APIs), with a portfolio spanning therapeutic areas like gastroenterology, oncology, cardiovascular, and pain management. It invests heavily in R&D (8-15% of sales annually), driving innovation and securing exclusive generic drug approvals, such as 180-day exclusivity in the U.S. market. Strategic acquisitions, like Trigenesis Therapeutics and UCB SA’s brands, and partnerships, such as with Alvotech for biosimilars, enhance its global footprint and product offerings.

Financially, Dr. Reddy’s reported ₹31,229 crore in revenue and ₹5,448 crore in profit for FY2024, with a market cap of ~₹98,132 crore. Despite fluctuating net profit margins (7-20% over FY2015-FY2024), its integrated supply chain, regulatory expertise, and focus on high-growth areas like nutraceuticals and cell therapy position it for sustained growth. However, challenges include regulatory hurdles, competition in generics, and ethical criticism for continued operations in Russia.